Abstract
The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5 – 8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P<0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bartek J, Iggo R, Gannon J and Lane DP. . 1990 Oncogene 5: 893–899.
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Baker DF, Nakamura Y, White R and Vogelstein B. . 1989 Science 244: 217–221.
Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF and Linnoila RI. . 1992 Oncogene 7: 743–749.
Borresen AL, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ and Friend SH. . 1991 Proc. Natl. Acad. Sci. USA 88: 8405–8409.
Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar AF and Minna J. . 1994 Chest 106: 377S–381S.
Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B and Slamon DJ. . 1996 Oncogene 13: 1971–1981.
Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC and Minna JD. . 1990 Oncogene 5: 1603–1610.
Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, Chetty U, Mackay J, Macdonald M, Nakamura Y, Hoyheim B and Steel CM. . 1990 Lancet 336: 761–763.
Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Borresen AL, Cornelisse CJ and Devilee P. . 1994 Cancer Res. 54: 4200–4206.
de Anta JM, Jassen E, Rosell R, Martinez-Roca M, Jassem J, Martinez-Lopez E, Monzo M, Sanchez-Hernandez JJ, Moreno I and Sanchez-Cespedes M. . 1997 Oncogene 15: 2951–2958.
Finlay CA, Hinds PW and Levine AJ. . 1989 Cell 57: 1083–1093.
Fong KM, Kida Y, Zimmerman PV, Ikenaga M and Smith PJ. . 1995 Cancer Res. 55: 4268–4272.
Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K and Sugimachi K. . 1997 Br. J. Cancer 75: 1125–1130.
Gannon JV, Greaves R, Iggo R and Lane DP. . 1990 EMBO J. 9: 1595–1602.
Greenblatt MS, Bennett WP, Hollstein M and Harris C. . 1994 Cancer Res. 54: 4855–4878.
Hollstein M, Sidransky D, Vogelstein B and Harris CC. . 1991 Science 253: 49–53.
Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R and Takahashi T. . 1993 Cancer Res. 53: 1–4.
Iggo R, Gatter K, Bartek J, Lane D and Harris AL. . 1990 Lancet 335: 675–679.
Isobe T, Hiyama K, Yoshida Y, Fujiwara Y and Yamakido M. . 1994 Jpn. J. Cancer Res. 85: 1240–1246.
Jones MH and Nakamura Y. . 1992 Genes Chrom. Cancer 5: 89–90.
Kiyama M and Fujita T. . 1996 Biotechniques 21: 710–716.
Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K and Sekiya T. . 1992 Cancer Res. 52: 4799–4804.
Lohmann D, Ruhri C, Schmitt M, Graeff H and Hofler H. . 1993 Diagn. Mol. Pathol. 2: 36–41.
Minna JD. . 1991 Harrison's Principles of Internal Medicine (edition 12). Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS and Root RK (eds).. McGraw-Hill: USA pp. 1102–1110.
Moore DF and Lee JS. . 1996 Lung Cancer: Principles and Practice. Pass HI, Mitchell JB, Johnson DH and Turrisi AT (eds).. Lippincott-Raven Publishers: Philadelphia pp. 481–494.
Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, Sugio K, Yasumoto K and Sugimachi K. . 1995 Ann. Oncol. 6: S9–S13.
Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shirakusa T. . 1993 J. Natl. Cancer Inst. 85: 2018–2023.
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B. . 1989 Nature (Lond.) 342: 705–708.
Ohno A, Hirashima T, Kubo A, Masuda N, Takada N, Fujiwara H, Yasumitsu T, Kikui M, Fukuoka M and Nakagawa K. . 1997 Int. J. Oncol. 10: 521–528.
Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M and Yokota J. . 1991a Cancer Res. 51: 5157–5176.
Okamoto A, Sameshima Y, Yamada Y, Teshima S, Terashima Y, Terada M and Yokota J. . 1991b Cancer Res. 51: 5632–5636.
Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV and Lane DP. . 1990 Proc. Natl. Acad. Sci. USA 87: 7555–7559.
Sakamoto T, Nomura N, Mori H and Wake N. . 1996 Gynecol. Oncol. 63: 173–179.
Sameshima Y, Matsuno Y, Hirohashi S, Shimosato Y, Mizoguchi H, Sugimura T, Terada M and Yokota J. . 1992 Oncogene 7: 451–457.
Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ and Godwin AK. . 1996 Cancer Res. 56: 1997–2002.
Shiseki M, Kohno T, Adachi J, Okazaki T, Otsuka T, Mizoguchi H, Noguchi M, Hirohashi S and Yokota J. . 1996 Genes Chrom. Cancer 17: 71–77.
Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE and Kovach JS. . 1992 J. Natl. Cancer Inst. 84: 246–252.
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD. . 1989 Science 246: 491–494.
Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ and Steel CM. . 1992 Int. J. Cancer 50: 528–532.
Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ and Baylin SB. . 1995 Nat. Med. 1: 570–577.
WHO.. 1981 Histological Typing of Lung Tumors, No. 1, Ed. 2. Geneva: WHO.
Yokota J and Sugimura T. . 1993 FASEB J. 7: 920–925.
Yokota J, Wada M, Shimosato Y, Terada M and Sugimura T. . 1987 Proc. Natl. Acad. Sci. USA 84: 9252–9256.
Acknowledgements
This work was supported in part by a Grant-in-Aid from the Ministry of Health and Welfare for the 2nd-term Comprehensive 10 – Year Strategy for Cancer Control, and Grants-in-Aid from the Ministry of Health and Welfare, from the Foundation for Promotion of Cancer Research and from the Naito Foundation, Japan.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tomizawa, Y., Kohno, T., Fujita, T. et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18, 1007–1014 (1999). https://doi.org/10.1038/sj.onc.1202384
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202384
Keywords
This article is cited by
-
Aqueous extract of Sapindus mukorossi induced cell death of A549 cells and exhibited antitumor property in vivo
Scientific Reports (2018)
-
Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer
Annals of Nuclear Medicine (2003)
-
Recent advances in the molecular diagnosis of lung cancer
Oncogene (2002)
-
Assessing TP53 status in human tumours to evaluate clinical outcome
Nature Reviews Cancer (2001)